ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?

被引：1
|
作者：
Kumar, Naveen [1 ]
机构：
[1] Medanta Hosp, Dept Urol, Patna, Bihar, India
来源：
INDIAN JOURNAL OF UROLOGY | 2022年 / 38卷 / 03期
关键词：
D O I：
10.4103/iju.iju_81_22
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：238 / 239
页数：2
相关论文
共 50 条
  • [41] Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
    Arnold Lee
    Targeted Oncology, 2023, 18 : 793 - 800
  • [42] Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Montesa-Pino, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe
    Tammela, Teuvo L. J.
    Suzuki, Hiroyoshi
    Utriainen, Tapio
    Fu, Cheng
    Uemura, Motohide
    Mendez-Vidal, Maria J.
    Maughan, Benjamin L.
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12): : 1132 - 1142
  • [43] Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Azad, Arun A.
    Tran, Ben
    Davis, Ian D.
    Parente, Phillip
    Evans, Melanie
    Wong, Shirley
    Brown, Stephen
    Evans, Sue
    Millar, Jeremy
    Murphy, Declan G.
    Papa, Nathan
    INTERNAL MEDICINE JOURNAL, 2022, 52 (08) : 1339 - 1346
  • [44] ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Kuronya, Zsofia
    Sukosd, Farkas
    Varga, Linda
    Biro, Krisztina
    Gyergyay, Fruzsina
    Geczi, Lajos
    Nagyivanyi, Krisztian
    Jorgo, Kliton
    Szarvas, Tibor
    Kovacs, Agnes
    Laczo, Ibolya
    Varga, Zoltan
    Posfai, Boglarka
    Pepo, Judit
    Maraz, Aniko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (04) : 289.e1 - 289.e9
  • [45] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
    von Bueren, Moritz
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
  • [46] Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer
    Boegemann, Martin
    UROLOGIE, 2023, 62 (04): : 354 - 359
  • [47] Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer
    Kwan, Edmond M.
    Azad, Arun A.
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 617 - 619
  • [48] Adding Docetaxel to Androgen-Deprivation Therapy in Newly Diagnosed Metastatic Prostate Cancer
    Vogelzang, Nicholas J.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2014, 10 (03) : 10 - 11
  • [49] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [50] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Pui San Tan
    Pedro Aguiar
    Benjamin Haaland
    Gilberto Lopes
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 516 - 523
12345